SJÖGREN’S · ACA
Sjögren’s and anticentromere antibodies
Understanding a positive ACA result
A positive ACA result is a clue about your immune system. Its meaning depends on your symptoms, examination, other antibodies and tests of how your organs are working. Some people have Sjögren’s with these antibodies; some have systemic sclerosis or another autoimmune condition; others do not have an established disease. The result alone does not tell you which situation applies or what will happen next.
If you are opening your laboratory report for the first time, start with questions 1–4. If Sjögren’s is already established, questions 5–12 explain how the result may affect practical decisions. Questions 13–15 cover symptoms that should not wait, research and preparing for a useful appointment. Every section remains available whichever route you choose.
What are ACA, and why were they tested?
ACA is short for anticentromere antibodies. Antibodies are proteins made by the immune system; these antibodies recognize proteins at the centromeres, parts of chromosomes inside cells. ACA may be found during an ANA test, which looks for antinuclear antibodies, or through a more specific test. On a report, “centromere pattern” or “AC-3” describes a pattern seen under the microscope. “CENP-B” names one centromere protein that a separate antibody test can target. These results are related, but they are not identical tests. [R01]
To understand the result, start with why the test was ordered: dry eyes and mouth, fingers changing color in the cold, a positive ANA, or another finding. A result above the laboratory’s cutoff means the test detected antibodies above that method’s threshold. The number does not directly measure damage to an organ.
Bring the complete report, including its reference range and method if listed. A screenshot showing only “positive” omits useful information. Do not confuse anticentromere antibodies with anticardiolipin antibodies: they are different tests, and a centromere result alone is not a reason to take a blood thinner.
A high number does not automatically mean severe disease, and a lower number does not show that an affected organ has recovered. Methods and reference ranges differ between laboratories. If the result is weak or unexpected, clarification can be useful; once the finding is established, repeatedly checking the same antibody usually answers a different question from whether your eyes, lungs or circulation need care.
SSA is negative and ACA is positive. Can this still be Sjögren’s?
Yes. A negative SSA result does not rule out Sjögren’s. SSA is an important antibody in this disease, but not everyone with Sjögren’s has it. A positive ACA result also cannot establish the diagnosis on its own. [R02] [R15]
Further assessment may include measuring tear production, examining the eye surface and measuring saliva production. Sometimes a small sample of salivary-gland tissue is taken from inside the lower lip: a lip biopsy. It looks for a characteristic pattern of inflammation. The test is most useful when its result would change the diagnosis or the next step in care. A sample that is too small, or shows only nonspecific inflammation, may leave the question open. [R02] [R15]
The 2016 ACR/EULAR classification criteria were developed to make groups in research studies comparable. They can support assessment, but clinical diagnosis also requires your history, examination and consideration of other causes. In these classification criteria, ACA does not replace SSA. “Objective dryness tests” means tests that measure tear or saliva production, or injury to the eye surface, rather than relying only on how dry you feel. [R02] [R15]
For example, an SSA-negative person may meet the research classification criteria through a biopsy showing the required pattern plus an eye or saliva test that meets the specified threshold, provided the other requirements are met. “Chronic inflammation” alone in a biopsy report does not necessarily describe that pattern. Ask whether there was enough tissue and whether the characteristic finding was present. Salivary-gland ultrasound can add information, but it does not automatically replace the biopsy or the other tests. [R02] [R15]
Medicines that cause dryness, eyelid problems and other conditions should be assessed too. Agree with your clinician which further test would clarify the diagnosis, or whether another explanation fits the findings better. Care for dry eyes and mouth can begin while that question is being resolved. [R15]
What if both ACA and SSA are positive?
Two positive antibodies do not automatically mean two diseases. Nor can the risks associated with each antibody simply be added together. The combination helps your clinician decide which symptoms and examination findings need closer attention.
For example, one part of the discussion may concern dryness and other Sjögren’s manifestations, while another concerns fingers that change color, the skin examination or the small vessels around the nails. The actual findings determine whether another disease is present. Studies have separated ACA-only and ACA/SSA-positive groups because their average features can differ. [R05]
If reports seem to conflict, ask which SSA test was used. Ro52 and Ro60 are different protein targets; laboratories may report antibodies to them separately or use a combined SSA test. Clarifying the method may explain the difference without repeating every antibody panel. Ask which diagnoses are established, which findings need follow-up and what each treatment is intended to improve.
During the visit, separate what you feel now, evidence of current inflammation, lasting damage and any confirmed additional disease. Treatment is chosen for the findings that need it. If you are planning a pregnancy, SSA has its own importance even if ACA was the first result that drew attention. [R13]
Does ACA mean scleroderma now—or later?
ACA is associated with systemic sclerosis, also called systemic scleroderma, but a positive antibody result does not establish that diagnosis. Systemic sclerosis can affect the skin, blood vessels and internal organs. Your clinician looks for a combination of symptoms, examination findings and test results. [R08] [R09]
There are also people with ACA-positive Sjögren’s who do not have systemic sclerosis. Follow-up helps distinguish a stable pattern from one that is changing. A person whose only finding is a laboratory result is not in the same situation as someone with Raynaud’s, puffy fingers and characteristic vascular changes.
You may encounter striking percentages online. Often they come from small or highly selected groups and cannot tell you your own chance of developing another disease. A more useful question is: “What findings do I have now, and what change would make us reassess?” A monitoring plan can be sensible without treating a possible future diagnosis as already established.
Findings that may change the assessment include persistent puffy fingers, tightening skin, fingertip pits or ulcers, and a characteristic pattern on nailfold examination. There can also be organ involvement with little obvious skin change. Ask whether the conclusion is established systemic sclerosis, a possible early pattern, or no current evidence of it. These conclusions lead to different follow-up plans; none can be selected from ACA alone. [R08] [R09]
Why do my fingers change color in the cold?
Raynaud’s phenomenon is a temporary change in blood flow to the fingers or toes, often triggered by cold or emotional stress. Fingers may become pale, bluish and then red as circulation recovers; not everyone sees every color. Numbness, tingling or pain may accompany an episode.
Describe the pattern and recovery. A photograph taken during a natural episode can help, but do not deliberately expose your hands to cold to produce one. Warm the whole body and hands gently; avoid burns from very hot water or direct heaters, especially when sensation is reduced. Medication and nicotine exposure can be relevant to the assessment.
Nailfold capillaroscopy is a magnified examination of the tiny blood vessels beside the nails. Certain patterns can help your clinician assess whether Raynaud’s is associated with another disease; a single unusual-looking vessel does not settle the diagnosis. A finger that stays very painful or discolored, a new ulcer or a blackened area needs prompt assessment. The section on urgent changes below explains when to seek help. [R09]
If attacks repeatedly interfere with daily life, medicines that widen blood vessels may help. Their choice depends on blood pressure, other medicines and whether there is tissue injury. A new ulcer needs assessment even if similar color changes have occurred for years. Record how long recovery takes and whether one finger behaves differently; these details can be more useful than counting every attack. [R09]
How can my eyes and mouth be so dry when blood tests look calm?
Blood tests do not directly measure the protective layer of tears on your eyes or the amount of saliva in your mouth. Dryness can interfere with reading, speaking, eating and sleep, and can damage dental health even when blood markers of inflammation are normal.
It helps to separate four things: how you feel; how much fluid the glands produce; what the eye or mouth surface looks like; and whether there is inflammation or established damage. These can move in different directions. A person can have meaningful symptoms with subtle surface findings, or surface injury that causes surprisingly little pain.
Care should therefore have specific goals: easier daily activities, a protected eye surface and fewer dental complications. Local treatment may still be needed when systemic treatment is effective. The detailed dryness guide explains lubricants, prescription eye treatments, saliva-stimulating medicines, dental prevention and selected procedures. None becomes unnecessary simply because ACA or another blood result changes. [R14] [R15]
Some studies found lower tear or saliva production in ACA-positive groups; others did not find the same pattern. An average for a group cannot show how much working gland tissue you have. An ultrasound change also cannot prove that all dryness comes from irreversible scarring. Ask what can be improved now: moisture, inflammation on the eye surface, remaining saliva production, a medicine that causes dryness, or prevention of cavities. [R03] [R06] [R16]
Do I need lung or heart tests?
The answer depends on your clinical findings and whether systemic sclerosis is also present. Tell your clinician about persistent cough, new breathlessness, reduced walking tolerance, chest symptoms or fainting. Describe what you could do before and what has changed; that often conveys more than “I feel tired.”
Breathing tests measure different aspects of lung function. DLCO estimates how well gas passes from the air spaces into the blood; a low result has more than one possible cause. An echocardiogram uses ultrasound to assess the heart and can help investigate certain causes of breathlessness. Neither test, by itself, says that ACA has damaged an organ.
The follow-up plan differs for Sjögren’s alone and for confirmed systemic sclerosis. In systemic sclerosis, regular screening can be needed even without symptoms. ACA positivity alone does not justify automatically ordering every test each year. Equally, new unexplained breathlessness needs assessment even if previous tests or a disease-activity score were reassuring. [R09] [R10]
The 2026 ERS/EULAR guidance also allows consideration of a detailed chest CT, called high-resolution CT or HRCT, when a person with Sjögren’s has a higher overall risk of interstitial lung disease. This means inflammation or scarring in the tissue around the lung’s tiny air sacs. Screening may be considered even without obvious symptoms; this is a conditional recommendation because the evidence is limited. [R24]
Normal breathing tests do not replace a CT when imaging is indicated. The decision depends on the whole risk assessment, not ACA alone. Established lung disease often needs closer monitoring. Ask what the proposed test is checking and how the result would change care. [R24]
What is the connection with liver tests or itching?
ACA can occur in people with autoimmune liver conditions, but it does not diagnose one. Primary biliary cholangitis, or PBC, affects small bile ducts in the liver. Autoimmune hepatitis, or AIH, involves a different pattern of liver inflammation. Their evaluation requires more than an anticentromere result. [R11]
Ask which liver test is abnormal and whether the change persists. Alkaline phosphatase, often abbreviated ALP, can rise because of the liver or bile ducts, but it can also come from bone. Further blood tests, a review of medicines and imaging such as ultrasound help identify the source before a diagnosis is assigned. [R11]
Persistent itching without an obvious skin explanation can be worth mentioning, particularly with abnormal tests. Yellow eyes or skin, dark urine, pale stools or worsening symptoms call for earlier assessment. Common causes, including medication effects and metabolic liver disease, remain possible. An autoimmune explanation should be evaluated when appropriate without becoming the default explanation for every abnormal result.
It is useful to bring results over time, not only the latest abnormal value. Also list supplements and nonprescription products. If an autoimmune liver condition is confirmed, its treatment and monitoring have their own goals; changing a Sjögren’s medicine does not automatically treat a bile-duct problem. Do not start an advertised “liver cleanse” while the cause is being investigated.
Is trouble swallowing always from dryness?
Saliva helps moisten food, but swallowing also requires coordinated muscles and a normally functioning food pipe. Dry food that becomes easier with a sip of water is a different problem from food repeatedly sticking, pain on swallowing, choking or coughing during meals.
Dryness may coexist with reflux, where stomach contents come back up into the esophagus, or food pipe. Infection, narrowing or problems with the movements that push food toward the stomach can also cause difficulty. Confirmed systemic sclerosis makes these movement problems especially relevant. ACA alone does not identify the cause. The type of difficulty helps your team choose an oral examination, a swallowing assessment, endoscopy or another test. [R09]
Report progressive symptoms or unintentional weight loss. If food becomes acutely stuck or you cannot swallow your saliva, seek urgent care. While the cause is being evaluated, adapting food texture and moisture may help; repeatedly eliminating more foods is not a substitute for understanding the problem. Ask a pharmacist before crushing tablets, because some formulations must stay intact.
Tell the team whether the difficulty concerns starting a swallow or food moving down afterward, and whether it occurs with solids, liquids or both. Mention a wet-sounding voice after meals, repeated chest infections or a falling weight. A reflux medicine can reduce acid exposure without correcting abnormal movement of the food pipe. These distinctions help choose a test that answers the right question.
Does ACA change my lymphoma risk or overall outlook?
Sjögren’s can increase the risk of some lymphomas, cancers of a type of white blood cell called lymphocytes. ACA positivity does not provide a reliable personal risk percentage. Some concerning reports studied people with both Sjögren’s and systemic sclerosis. Their results cannot simply be applied to everyone with ACA. [R12] [R15]
The practical assessment looks for findings such as persistent one-sided gland enlargement, a new or growing lump, enlarged lymph nodes, unexplained fever or weight loss, and relevant blood abnormalities. These findings have several possible causes; they need evaluation rather than an assumption of cancer.
A 2026 observational study of people with Sjögren’s did not find a statistically clear association between anti-CENP-B and cancer, death or interstitial lung disease. That does not prove equal long-term risk: few events and limited follow-up restrict certainty. Your plan should specify which changes to report, how persistent gland swelling will be investigated and when you will be reviewed. One antibody result should not be used either to frighten you or to dismiss a new symptom. [R31] [R15]
A swelling that comes and goes with infection or meals can have a different explanation from a persistent focal lump. Both deserve an appropriate history and examination. If sampling is needed, the clinician chooses the method for the suspected problem; another ACA blood test cannot identify the nature of a lump. The useful follow-up plan explains what is stable, what has changed and who will assess a new finding.
Should the antibody be treated until it becomes negative?
Treatment aims to improve health and protect function. A meaningful target might be healing an eye surface, preventing cavities, improving inflammatory joint disease or controlling a confirmed organ problem. Making an antibody result negative is not, by itself, a demonstrated treatment goal for ACA-positive Sjögren’s.
For each medicine, ask what it is intended to improve and how that improvement will be measured. A medicine can help one manifestation while dryness still needs separate care. Increasing medicines that suppress the immune system solely because ACA remains positive can add side effects without addressing the problem that needs treatment. [R14] [R15]
Likewise, repeated ACA measurements do not replace examination, eye and dental assessment or testing of an organ that has become symptomatic. A repeat antibody test may be useful to clarify an unexpected or uncertain laboratory finding, but that is a different purpose from monitoring treatment success. Do not stop prescribed medication because an online description calls your antibody profile “mild.”
Examples make the goal clearer. Artificial tears and prescription eye drops protect or treat the eye surface; fluoride-based dental care helps prevent cavities; selected medicines stimulate the saliva that the glands can still produce. Hydroxychloroquine may be chosen for certain inflammatory manifestations, but it does not reliably relieve dryness. Stronger medicines that suppress the immune system need a defined indication, such as significant organ inflammation. In adults who also have systemic sclerosis, steroids require particular caution because they are associated with a serious kidney complication called scleroderma renal crisis. [R09] [R14] [R15]
Agree how benefit and side effects will be assessed, and when the treatment will be reviewed. Benefit might mean fewer painful attacks, healing of the eye surface, less joint inflammation or stable organ function. The plan should also explain what would lead to continuing, adjusting or stopping the medicine. A positive ACA result alone should not decide that. [R14] [R15]
What changes with pregnancy, medicines or other illnesses?
ACA is different from anti-Ro/SSA and anti-La/SSB. Anti-Ro/La can affect the baby during pregnancy, including the electrical conduction that controls the heartbeat, and require a separate discussion about monitoring. Those risks should not automatically be assigned to ACA alone. If both ACA and SSA are present, both belong in the planning discussion. [R13]
Before pregnancy, review disease activity, organ function and medicines with the clinicians responsible for your rheumatic and obstetric care. An established overlap condition can change the plan. A complete review is more useful than stopping treatment on your own or focusing only on the antibody level.
Outside pregnancy, kidney or liver disease, infection risk, heart and lung findings, and other medicines also affect treatment choices. Some medicine-related risks differ when systemic sclerosis is present. A plan can address several conditions together: bring the complete medication list so the team can check benefits, side effects and interactions.
If you plan to become pregnant, review medicines before trying to conceive. Hydroxychloroquine can generally be used during pregnancy. Methotrexate and mycophenolate need to be stopped in advance according to a plan specific to each medicine. The team should also decide how to keep your disease controlled, so do not change treatment on your own. Bring the full antibody report and medication list to a preconception visit. [R13] [R30]
Which changes should not wait?
Emergency care now:
- Sudden weakness on one side, facial droop or difficulty speaking.
- Severe or sudden breathlessness; or fainting with concerning chest or breathing symptoms.
- Inability to swallow your saliva.
- A finger that remains very painful and cold, or develops a dark or black area.
Use local emergency services. The urgency comes from the symptom, not the antibody.
Assessment the same day:
- A painful red eye with reduced vision or marked sensitivity to light: seek urgent eye assessment.
- A new fingertip ulcer.
- Rapidly developing painful salivary-gland swelling with fever.
- Inability to drink enough fluids.
Severe symptoms or rapid deterioration may require emergency care.
Arrange an earlier medical review for progressive swallowing difficulty, yellow skin or eyes, persistent one-sided salivary-gland swelling, a growing lump, unexplained weight loss, reduced exercise tolerance or new persistent finger swelling. Do not wait for an annual visit to report these changes.
Stable longstanding symptoms can be addressed within the agreed care plan. This educational website is not a clinic messaging or emergency service.
What is being studied, and could my profile fit a trial?
Researchers are studying whether antibody groups reflect differences inside affected glands and whether those differences could guide treatment. Tissue and cell studies generate promising questions; they do not prove that a particular medicine works for an ACA-positive person. [R17]
Each trial has its own eligibility rules. The nipocalimab DAHLIAS trial required anti-Ro antibodies. The two cited dazodalibep programs allowed anti-Ro or rheumatoid factor (RF), another antibody found in blood tests. ACA alone may therefore be insufficient even when your clinical diagnosis of Sjögren’s is sound. Not meeting one trial’s rules does not make your illness less real or mean that treatment cannot help. [R19] [R20] [R21]
Before considering a trial, check four separate questions: Does its protocol allow your antibody profile? Were people with that profile actually enrolled? Were their treatment results reported separately? Is a site you can reach currently recruiting? The answer to one does not settle the others. The professional chapter compares selected programs, but cannot promise enrollment, an ACA-specific medicine or a benefit that has not been shown.
In the 2025 gland study, some centromere-positive participants were included using a rule adapted for that study, counting centromere antibodies toward classification. This has not added ACA to the standard 2016 ACR/EULAR classification criteria. The tissue findings also do not establish a clinical diagnosis from ACA alone. Differences between small groups need confirmation before they can guide a medicine choice. A successful Sjögren’s trial does not necessarily show benefit in people with ACA but no SSA. [R17] [R02]
The NEPTUNUS-2 protocol for ianalumab provided an SSA-negative exception: a positive salivary-gland biopsy had to be confirmed by central expert review. This group could make up no more than 10% of the participants, and all other eligibility requirements still applied. ACA alone was insufficient, and the exception does not prove benefit in an ACA subgroup. [R18]
The checked registry record, updated on 17 June 2026, says “active, not recruiting”: it is not enrolling new participants. For any future study, check its current record and protocol with the study team. [R18]
How can I make the next appointment more useful?
Bring the complete antibody report, a brief symptom timeline, relevant eye and dental findings, biopsy or imaging reports, and a medication list. Include nonprescription products that can affect dryness or circulation. Photos of naturally occurring finger-color changes can be helpful. There is no need for an elaborate daily diary if a short record captures the change.
| Useful question | What a clear answer should explain |
|---|---|
| What diagnosis is established now? | The findings supporting it and what remains uncertain |
| What does ACA add in my situation? | Which part of the assessment or follow-up it changes |
| Do I have evidence of systemic sclerosis? | Actual examination, vascular or organ findings |
| Which test would change the next decision? | The question being answered, not just a test list |
| What is each treatment meant to improve? | A practical target and a way to assess benefit |
| What should make me contact the team earlier? | Specific changes and an appropriate contact route |
The aim is a plan you understand: what is known, what needs clarification, what is being treated and what change would prompt a different decision.
A short practical record can use three lines: “what changed,” “what I can no longer do,” and “what I hope treatment will improve.” Add the date of onset and one concrete example, such as needing to stop halfway up a familiar staircase. Before leaving, clarify the next review, responsibility for any pending result and the route for earlier contact if the agreed warning signs occur.
Sources
- [R01] ICAP: AC-3 centromere pattern
- [R02] 2016 ACR/EULAR classification criteria for Sjögren’s
- [R03] Baer et al. SICCA: ACA and exocrine dysfunction (2016)
- [R05] Tsukamoto et al. Four ACA/SSA profiles (2018)
- [R06] Shimizu et al. ACA and salivary-gland ultrasound (2024)
- [R08] 2013 ACR/EULAR systemic-sclerosis classification criteria
- [R09] BSR systemic-sclerosis guideline (2024)
- [R10] Sjögren’s Foundation: pulmonary clinical practice guidance
- [R11] AASLD primary biliary cholangitis practice guidance
- [R12] Baldini et al. ACA-positive SSc/Sjögren overlap (2013)
- [R13] ACR reproductive-health guideline (2020)
- [R14] EULAR topical and systemic Sjögren’s treatment recommendations
- [R15] BSR adult and juvenile Sjögren disease guideline (2024/2025)
- [R16] Park et al. ACA in the Korean KISS cohort (2021)
- [R17] Inamo et al. Single-cell and spatial profiling of Sjögren’s (2025)
- [R18] Ianalumab NEPTUNUS-2: NCT05349214, record updated 17 June 2026
- [R19] Dazodalibep systemic-activity study NCT06104124
- [R20] Dazodalibep symptom study NCT06245408
- [R21] Nipocalimab DAHLIAS primary trial report (2025)
- [R24] ERS/EULAR connective tissue disease-associated ILD guideline (2026)
- [R30] EULAR antirheumatic drugs in reproduction, pregnancy and lactation: 2024 update (2025)
- [R31] Lei et al. Anti-centromere protein B antibody positivity in primary Sjögren’s disease: clinical features and prognostic implications (2026)
Personal educational publication by Olga Goodman, MD. This is not a clinic portal or an emergency service. Any private expert service is separate from clinic accounts and insurance billing. Reuse requires attribution and a link to the original publication.